{"id":"NCT00805675","sponsor":"Novartis Pharmaceuticals","briefTitle":"Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB","officialTitle":"A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2010-12","completion":null,"firstPosted":"2008-12-10","resultsPosted":"2012-02-28","lastUpdate":"2012-02-28"},"enrollment":83,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis B Virus"],"interventions":[{"type":"DRUG","name":"Telbivudine","otherNames":[]},{"type":"DRUG","name":"Tenofovir","otherNames":[]},{"type":"DRUG","name":"Telbivudine plus tenofovir","otherNames":[]}],"arms":[{"label":"Telbivudine 600 mg monotherapy","type":"EXPERIMENTAL"},{"label":"Tenofovir disproxil fumarate 300 mg monotherapy","type":"ACTIVE_COMPARATOR"},{"label":"Telbivudine 600 mg and Tenofovir 300 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs. tenofovir DF 300 mg once daily (QD) or vs telbivudine 600 mg monotherapy daily (QD). This is an open labeled, active controlled, viral kinetics study which means the subjects and study doctor will know what study drug subjects have been assigned. This study is open to male and female subjects, \\<40 years of age, who have been infected with HBV for at least 6 months and have not received oral treatment for HBV.","primaryOutcome":{"measure":"Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Telbivudine 600 mg Monotherapy","deltaMin":-3.852,"sd":0.933},{"arm":"Tenofovir Disproxil Fumarate 300 mg Monotherapy","deltaMin":-4.175,"sd":0.7476},{"arm":"Telbivudine 600 mg and Tenofovir 300 mg","deltaMin":-4.374,"sd":0.9774}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Influenza","Influenza like illness","Abdominal Pain Upper","Oropharyngeal pain","Dizziness"]}}